Daffodil
Senior Member
- Messages
- 5,875
PLease behold: New adaptive immunotherapy treatments in the pipeline for EBV related diseases! One beyond phase 3!
http://www.atarabio.com/pipeline/
http://www.atarabio.com/pipeline/
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
probably not too soonGreat! Wonder when it might be available in Canada and how to get access to it.
Znewby
i wonder if someone can contact the company about doing a trial at some point, for me/cfs....It'll be extremely expensive for at least 20 years and likely not approved for ME/CFS so unlikely to be subsidised in countries that have subsidised drug services.
Am I reading it correctly that the drug that’s in phase 3 is a rituximab?PLease behold: New adaptive immunotherapy treatments in the pipeline for EBV related diseases! One beyond phase 3!
http://www.atarabio.com/pipeline/
what do you mean "a rituximab"?Am I reading it correctly that the drug that’s in phase 3 is a rituximab?
what do you mean "a rituximab"?
Yes, that is what I was referring to. Thank you, I’m not scientifically minded by any stretch, so I’m unsure what rituximab refractory means?FYI... I do not know what this means, but I believe it is what @nryanh94 is referring to.
View attachment 27893
It means when rituxan doesnt workFYI... I do not know what this means, but I believe it is what @nryanh94 is referring to.
View attachment 27893
Ive posted about this guy previously and there is an article of how he put an ms patient into remission. Probably didnt get many views as a certain dr didnt believe ebv had anything to do with ms and basically shut down much debate on the thread or any thread that didnt fit his agenda.
https://msra.org.au/project/immune-control-of-epstein-barr-virus-in-ms/
Some interesting excerpts from the link you gave @heapsreal ...
"A large body of evidence indicates that infection with Epstein-Barr virus (EBV) has a role in MS. Prof Pender has shown that people with MS have decreased immunity to EBV which could allow the accumulation of EBV-infected cells in the brain and the subsequent development of MS. This project will look at specific immune cells involved with the response to EBV infection known as CD8 T cells."
"Professor Pender has also examined blood samples from a large number of people with all forms of MS including the earliest signs of MS, known as Clinically Isolated Syndrome (CIS). The CD8 effector memory cell deficiency is present in all of these stages and types of the disease, including the very earliest stage, CIS, suggesting that is a cause, rather than a consequence, of the disease. He has also shown that other T cell types are also decreased over the course of disease, contributing to overall T cell exhaustion."
"An exciting development in this direction was revealed earlier this year, when Professor Pender and his colleagues published the promising results for a patient with secondary progressive MS who was treated with CD8 cells primed to recognise EBV. The therapy had no adverse effects and the patient showed clinical improvement with reduced disease activity. This is the first time that this type of therapy, known as adoptive immunotherapy, has been used to treat MS or any other autoimmune disease. Professor Pender and colleagues are now planning to undertake a phase I clinical trial of the therapy."
Updated: 13 April 2015
PROFESSOR MICHAEL PENDER
UNIVERSITY OF QUEENSLAND, QLD
https://msra.org.au/project/immune-control-of-epstein-barr-virus-in-ms/
Pender has published extensively and is still very actively building on his research:
https://researchers.uq.edu.au/researcher/321
Ron Davis mentioned in his latest brief video this week that his team will be looking at the T-cell activation in ME.
Could there be something in Pender's work of interest in ME?
I wonder if Ron is aware of Pender's research with MS in Australia.
@Janet Dafoe (Rose49)
For the current study, the researchers isolated T cells from patients with MS and grew them in the laboratory with fragments of Epstein-Barr virus in the hope of expanding the number of T cells able to attack B cells infected with the virus. The cells are then readministered to the patients as a course of four dose-escalating injections over a 6-week period. Dr Pender noted that this approach has been used to treat certain malignancies also thought be associated with Epstein-Barr virus.